Weibing Leng

433 total citations
16 papers, 325 citations indexed

About

Weibing Leng is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Weibing Leng has authored 16 papers receiving a total of 325 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 6 papers in Oncology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Weibing Leng's work include Colorectal Cancer Treatments and Studies (5 papers), Gastric Cancer Management and Outcomes (4 papers) and MicroRNA in disease regulation (3 papers). Weibing Leng is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), Gastric Cancer Management and Outcomes (4 papers) and MicroRNA in disease regulation (3 papers). Weibing Leng collaborates with scholars based in China. Weibing Leng's co-authors include Hongwei Xia, Qiulin Tang, Qingjuan Chen, Xiaojun Ge, Feng Bi, Dandan Yuan, Xiaohui Pang, Liang Chen, Dandan Yuan and Yuchen Zhang and has published in prestigious journals such as PLoS ONE, Medicine and Oncotarget.

In The Last Decade

Weibing Leng

14 papers receiving 322 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Weibing Leng China	7	241	193	49	43	40	16	325
Jitao Zhou China	8	219 0.9×	183 0.9×	53 1.1×	77 1.8×	35 0.9×	16	345
Shinya Kidogami Japan	12	236 1.0×	114 0.6×	58 1.2×	66 1.5×	35 0.9×	26	321
Pouria Jandaghi Canada	10	261 1.1×	128 0.7×	18 0.4×	55 1.3×	25 0.6×	14	327
Jinxue Tong China	9	270 1.1×	138 0.7×	27 0.6×	90 2.1×	30 0.8×	19	347
Zhigang Jie China	7	322 1.3×	304 1.6×	16 0.3×	28 0.7×	35 0.9×	7	407
Yi Zang China	9	345 1.4×	227 1.2×	19 0.4×	95 2.2×	16 0.4×	12	434
Bingwei Ye United States	9	250 1.0×	162 0.8×	26 0.5×	39 0.9×	29 0.7×	12	349
Xiang Ma China	13	281 1.2×	253 1.3×	16 0.3×	66 1.5×	35 0.9×	26	435
Tania Vázquez Spain	5	158 0.7×	180 0.9×	30 0.6×	43 1.0×	52 1.3×	7	295

Countries citing papers authored by Weibing Leng

Since Specialization

Citations

This map shows the geographic impact of Weibing Leng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weibing Leng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weibing Leng more than expected).

Fields of papers citing papers by Weibing Leng

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weibing Leng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weibing Leng. The network helps show where Weibing Leng may publish in the future.

Co-authorship network of co-authors of Weibing Leng

This figure shows the co-authorship network connecting the top 25 collaborators of Weibing Leng. A scholar is included among the top collaborators of Weibing Leng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weibing Leng. Weibing Leng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Leng, Weibing, et al.. (2025). GABRD Accelerates Tumour Progression via Regulating CCND1 Signalling Pathway in Gastric Cancer. Journal of Cellular and Molecular Medicine. 29(7). e70485–e70485.

Zhou, Yuwen, Qian Xu, Jialing Wang, et al.. (2024). Efficacy and safety of RS plus bevacizumab versus RS plus fruquintinib as the third‐line therapy in patients with refractory metastatic colorectal cancer: A real‐world propensity score matching study. Journal of Evidence-Based Medicine. 17(3). 667–674. 1 indexed citations

Leng, Weibing, et al.. (2024). E203K mutation in MAP2K1 (MEK1) causes acquired resistance to PD-1 blockade but responds to trametinib: a case report. Chinese Clinical Oncology. 13(6). 87–87.

Zhou, Yuwen, Xin Zhao, Peng Cao, et al.. (2024). Dynamic ctDNA-based analysis of drug-resistant gene alterations at RAS/BRAF wild-type metastatic colorectal cancer patients after cetuximab plus chemotherapy as the first-line treatment. International Immunopharmacology. 131. 111887–111887. 1 indexed citations

Chen, Xiaorong, Weibing Leng, Yuwen Zhou, et al.. (2023). Pathological response and safety of FOLFOXIRI for neoadjuvant treatment of high-risk relapsed locally advanced colon cancer: study protocol for a single-arm, open-label phase II trial. BMJ Open. 13(1). e062659–e062659. 2 indexed citations

Huang, Qian, et al.. (2021). Locally advanced gastroesophageal junction cancer with pathological complete response to neoadjuvant therapy: a case report and literature review. Annals of Translational Medicine. 9(6). 513–513. 5 indexed citations

Zhang, Weihan, et al.. (2021). A randomized phase II trial comparing capecitabine with oxaliplatin or docetaxel as first-line treatment in advanced gastric and gastroesophageal adenocarcinomas. Medicine. 100(17). e25493–e25493. 3 indexed citations

Xia, Hongwei, Qingjuan Chen, Ying Chen, et al.. (2016). The lncRNA MALAT1 is a novel biomarker for gastric cancer metastasis. Oncotarget. 7(35). 56209–56218. 93 indexed citations

Zhang, Yuchen, Hongwei Xia, Xiaojun Ge, et al.. (2014). CD44 acts through RhoA to regulate YAP signaling. Cellular Signalling. 26(11). 2504–2513. 55 indexed citations

10.

Yuan, Dandan, Hongwei Xia, Yuchen Zhang, et al.. (2014). P-Akt/miR-200 signaling regulates epithelial-mesenchymal transition, migration and invasion in circulating gastric tumor cells. International Journal of Oncology. 45(6). 2430–2438. 22 indexed citations

11.

Ge, Xiaojun, Qingjuan Chen, Yang Wu, et al.. (2014). Induced IGF-1R activation contributes to gefitinib resistance following combined treatment with paclitaxel, cisplatin and gefitinib in A549 lung cancer cells. Oncology Reports. 32(4). 1401–1408. 6 indexed citations

12.

Chen, Qingjuan, Xiaojun Ge, Yuchen Zhang, et al.. (2014). Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer. Oncology Reports. 31(4). 1863–1870. 86 indexed citations

13.

Pang, Xiaohui, et al.. (2013). Radiotherapy for gastric cancer: a systematic review and meta-analysis. Tumor Biology. 35(1). 387–396. 20 indexed citations

14.

Xia, Hongwei, Mingxing Li, Liang Chen, et al.. (2013). Suppression of RND3 activity by AES downregulation promotes cancer cell proliferation and invasion. International Journal of Molecular Medicine. 31(5). 1081–1086. 12 indexed citations

15.

Leng, Weibing, Xiaohui Pang, Hongwei Xia, et al.. (2013). Novel Split-Luciferase-Based Genetically Encoded Biosensors for Noninvasive Visualization of Rho GTPases. PLoS ONE. 8(4). e62230–e62230. 18 indexed citations

16.

Li, Libo, Qiulin Tang, Mingxing Li, et al.. (2013). [The effect of eukaryotic expression plasmid ARHI on gastric cancer].. PubMed. 44(1). 10–4, 20. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact